We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Inexpensive Diagnostic Device May Revolutionize Medical Care

By LabMedica International staff writers
Posted on 28 Feb 2017
A radically designed “lab on a chip” diagnostic device is expected to dramatically reduce the cost of isolating and characterizing rare cells and molecules, a process that is of critical importance in diagnosis of common lethal diseases such as malaria, tuberculosis, HIV, and cancer.

Point-of-care diagnostics in the developing world and resource-limited areas require numerous special design considerations to provide effective early detection of disease. More...
Of particular need for these contexts are diagnostic technologies featuring low costs, ease of use, and broad applicability. Investigators at Stanford University recently described a nanoparticle-inkjet-printable microfluidics-based platform that fulfilled these criteria and that is expected to significantly reduce the footprint, complexity, and cost of clinical diagnostics. This reusable 0.01 USD device is miniaturized to handle small sample volumes and can perform numerous analyses.

The device is a combination of microfluidics, electronics, and inkjet printing technology. It is in essence a two-part system: a clear silicone microfluidic chamber for housing cells resting on top of a reusable electronic strip. A regular inkjet printer was used to print the electronic strip onto a flexible sheet of polyester using commercially available conductive nanoparticle ink.

The device, which separates cells based on their size and intrinsic electrical properties, can perform label-free and rapid single-cell capture, efficient cellular manipulation, rare-cell isolation and selective analytical separation of biological species, sorting, concentration, positioning, enumeration, and characterization. The miniaturized format allows for small sample and reagent volumes. By keeping the electronics separate from microfluidic chips, the former can be reused and device lifetime is extended.

The process of manufacturing the device is significantly less expensive, time-consuming, and complex than traditional lab-on-a-chip platforms, requiring only an inkjet printer rather than skilled personnel and clean-room facilities. Production requires only about 20 minutes (versus up to weeks) and one US cent - an unprecedented cost in in clinical diagnostics.

“The genome project has changed the way an awful lot of medicine is done, and we want to continue that with all sorts of other technology that are just really inexpensive and accessible,” said senior author Dr. Ronald W. Davis, professor of biochemistry and genetics at Stanford University. “The motivation was really how to export technology and how to decrease the cost of things.”

A study describing the technology was published in the February 6, 2017, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Automated Urinalysis Solution
UN-9000
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.